Ultragenyx Pharmaceutical In (RARE) — Institutional Holders Breakdown (Q2 2026)

RARE ranks #2002 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

RARE is a disclosed holding of Cliff Asness (AQR Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.1% of that fund's own 13F portfolio.

316 institutions disclose a position in RARE, but none treat it as a major bet — even Eagle Health Investments LP, its most concentrated holder, allocates just 4.9% of its own portfolio to it.

BlackRock has added to its RARE position for two straight quarters, increasing it by $203.2M to reach $355.7M today.

Ken Griffin has trimmed its RARE position for two straight quarters, cutting it by $49.6M while still holding $11.6M.

RARE is down 0.1% today, but institutions show net buying of $628.2M this quarter — a divergence between today's price move and the underlying institutional flow.

RARE reported a net loss of $586.0M over the trailing twelve months.

• Not yet profitable — net loss of $586.0M over the trailing twelve months
• Revenue grew 17.5% year over year
• Net income declined year over year, from -$532.7M to -$586.0M
• Operating cash flow was negative, using $466.0M in cash
• Current ratio of 2.48x — enough short-term assets to cover short-term liabilities
• Total liabilities currently exceed total assets (negative shareholder equity)